The prime directive of biotech, pharma, and everyone who supports the space is to get medicines to the patients who need them — in time to make a difference. That timeline is the one we measure ourselves against.
In 1995, our founder's family lost his fifteen-year-old brother, William, to bacterial meningitis. The science was not where it needed to be. The operations to scale what existed were not where they needed to be either. That combination decides which families wait — and which families do not.
Phase 3 was built so that fewer families wait. It is why a search firm brings leaders together, publishes governance research, and refuses to treat a placement as a transaction. It is all the same work.
Read the full story →A boutique practice is only as good as what it refuses to compromise on. These are ours.
Get medicines to the patients who need them — in time to make a difference. This is the timeline that matters, and we measure our work against it.
Evidence beats opinion when deciding about people, capital, and platforms. It is why we bring leaders together to build research — and publish it — instead of keeping it in a drawer.
The right CTO at the right stage. The right CMC head before the first inspection. Leadership is what turns science into approved medicine.
Every engagement starts with a conversation — and a diagnostic — not a contract.
